NCT01273428

Brief Summary

Testing a drug and a device for the treatment of pressure ulcers, compared with current treatments.

Trial Health

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 3, 2010

Completed
1 month until next milestone

First Posted

Study publicly available on registry

January 10, 2011

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2011

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2011

Completed
Last Updated

September 12, 2012

Status Verified

January 1, 2011

First QC Date

December 3, 2010

Last Update Submit

September 10, 2012

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in Wound Bed Scores

    22 days

Secondary Outcomes (1)

  • Adverse Events

    22 days

Study Arms (3)

HP011-101

ACTIVE COMPARATOR
Drug: HP011-101

HP828-101

ACTIVE COMPARATOR
Device: HP-828-101

Standard Care

OTHER
Other: Standard Care

Interventions

HP011-101
HP828-101
Standard Care

Eligibility Criteria

Age12 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects must meet all of the following criteria to be eligible for the study:
  • Provide informed consent, or informed assent if less than 18 years of age.
  • Age 12 years or older, of either sex, and of any race or skin type, provided that their skin color, in the opinion of the Investigator, will not interfere with the study assessments.
  • Have a pressure ulcer ≥ 5 cm² and ≤ 100 cm² in area (measured as greatest length x perpendicular width of the area of non-blanching erythema or denuded skin, whichever is greater), and will remain hospitalized for at least three weeks.
  • Are capable of maintaining an adequate nutritional status.
  • All female subjects must have a negative urinary pregnancy test.
  • Have, within 12 weeks prior to screening, clinical laboratory test results indicating:
  • Serum albumin ≥ 3.0 g/dL (30 g/L)
  • Alkaline phosphatase, ALT, AST, BUN and serum creatinine levels \< 3x upper limit of the Healthpoint normal range (refer to Section 18.1.2)
  • HbA1C ≤ 12%
  • Hemoglobin ≥ 10 g/dL
  • The most recently obtained values must be evaluated against these criteria. If these values are not available from a blood sample within 12 weeks of screening, blood must be drawn at screening and these laboratory values determined.
  • For ulcers that will require surgical debridement prior to enrollment, the wound must be expected to remain a Stage I or Stage II partial thickness wound after debridement.

You may not qualify if:

  • Subjects meeting any of the following criteria are not eligible to enter the study:
  • Have a known hypersensitivity to any of the test articles or their components.
  • Have received therapy with another investigational agent within thirty (30) days of screening.
  • Are pregnant or nursing.
  • Are currently being treated with systemic antibiotics.
  • Have received systemic treatment with glucocorticoids for \> 10 consecutive days within 1 month prior to the start of the study.
  • Have received chemotherapy or radiation therapy within the past 5 years.
  • Have clinical evidence of bacterial or fungal infection of the wound per visual/clinical assessment.
  • Have a severe burn, immunodeficiency disorder, hematologic disorder, or metastatic malignancy.
  • Have had documented osteomyelitis in the wound area within 6 months prior to screening.
  • The Principal Investigator may declare any subject ineligible for a valid medical reason.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Pressure Ulcer

Interventions

Standard of Care

Condition Hierarchy (Ancestors)

Skin UlcerSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Quality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and Evaluation

Study Officials

  • Herbert B Slade, MD

    Healthpoint, Ltd

    STUDY CHAIR
0

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

December 3, 2010

First Posted

January 10, 2011

Primary Completion

June 1, 2011

Study Completion

November 1, 2011

Last Updated

September 12, 2012

Record last verified: 2011-01